BioSource Consulting Group
BioSource Consulting helps build successful biotechnology companies by integrating business strategy with innovative science. With over 35 years of practical scientific and business experience, they provide strategic consulting, support for entrepreneurs, educational resources, and support for biotech companies at all stages of development. Their mission is to solve the challenging problems that arise when building a biotech company, stimulating growth, accelerating product development, and improving financing opportunities.
Industries
Nr. of Employees
small (1-50)
Products
Biotechnology Entrepreneurship: Leading, Managing, and Commercializing Innovative Technologies (2nd edition)
A practical guide covering biotechnology entrepreneurship, commercialization processes, company building, regulatory, clinical development and fundraising topics.
The Business of Bioscience: What Goes Into Making a Biotechnology Product
A book recounting lessons on operational and business issues in building biotechnology companies and bringing products to market.
Biotechnology Entrepreneurship: Leading, Managing, and Commercializing Innovative Technologies (2nd edition)
A practical guide covering biotechnology entrepreneurship, commercialization processes, company building, regulatory, clinical development and fundraising topics.
The Business of Bioscience: What Goes Into Making a Biotechnology Product
A book recounting lessons on operational and business issues in building biotechnology companies and bringing products to market.
Services
End-to-end guidance linking scientific development to business strategy, milestone planning and financing options for early- and development-stage organizations.
Creation and optimization of investor slide decks, application of stage-appropriate valuation methods, and advising on fundraising timing and structure.
Technical and strategic preparation of competitive grant proposals and guidance on non-dilutive funding sources.
Due diligence assessments covering technical, regulatory, financial and operational risk to support investor decision-making or M&A activity.
Guidance on regulatory routes, submission timing and interactions for therapeutics, diagnostics and devices.
Develop clinical development plans, milestone schedules and provide implementation guidance for clinical testing.
End-to-end guidance linking scientific development to business strategy, milestone planning and financing options for early- and development-stage organizations.
Creation and optimization of investor slide decks, application of stage-appropriate valuation methods, and advising on fundraising timing and structure.
Technical and strategic preparation of competitive grant proposals and guidance on non-dilutive funding sources.
Due diligence assessments covering technical, regulatory, financial and operational risk to support investor decision-making or M&A activity.
Guidance on regulatory routes, submission timing and interactions for therapeutics, diagnostics and devices.
Develop clinical development plans, milestone schedules and provide implementation guidance for clinical testing.
Expertise Areas
- Strategic and product development consulting
- Technology assessment and product–market fit
- Clinical trial management and design
- Regulatory strategy and submission planning
Key Technologies
- Biomarker discovery
- Molecular diagnostics
- Protein biochemistry
- Biologics development
News & Updates
Pfizer faced a $2.3 billion settlement for unlawful marketing practices, including off-label drug promotion and sham requests from physicians.
BioSource - BioEntrepreneurship Book Launch
Introduction of the book 'Biotechnology Entrepreneurship: Leading, Managing, and Commercializing Innovative Technologies' as a resource for biotech entrepreneurs.
BioSource - BioEntrepreneurship Book Launch
Introduction of the book 'Biotechnology Entrepreneurship: Leading, Managing, and Commercializing Innovative Technologies' as a resource for biotech entrepreneurs.
The Business of Bioscience Book Overview
A comprehensive guide for biotech entrepreneurs covering product development, management, and funding.
Pfizer faced a $2.3 billion settlement for unlawful marketing practices, including off-label drug promotion and sham requests from physicians.
BioSource - BioEntrepreneurship Book Launch
Introduction of the book 'Biotechnology Entrepreneurship: Leading, Managing, and Commercializing Innovative Technologies' as a resource for biotech entrepreneurs.
BioSource - BioEntrepreneurship Book Launch
Introduction of the book 'Biotechnology Entrepreneurship: Leading, Managing, and Commercializing Innovative Technologies' as a resource for biotech entrepreneurs.
The Business of Bioscience Book Overview
A comprehensive guide for biotech entrepreneurs covering product development, management, and funding.